# OnCo record nct03473743 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03473743/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03473743", "NCT03473743" ;
  schema:name "A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer"@en ;
  schema:description "A phase 1/2 trial of Erdafitinib, Cetrelimab, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03473743/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03473743> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2018-04-05" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/drugs/cetrelimab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> .